SARS-CoV-2(2019-NCoV) S1 (D614G), His Tagged Spike S1 Recombinant Protein
To support COVID-19 research, we produce recombinant SARS-CoV-2 proteins which can be used as
antigen for analytic and immune-diagnostic purposes and also for vaccine development
Catlog # NTSB-001
Why choose Stellixir Biotech SARS-CoV-2 Spike Protein?
- Val16-Lys1211 with a C-term His tag.
- Stabilizing mutations K986P and V987P promote the prefusion conformation.
- Two mutations, R682S and R685S, eliminate a Furin protease cleavage site.
- Guaranteed Bioactivity and High Purity: Bioactivity tested by functional ELISA and purity determined by SDS-PAGE to be greater than 95% (range 95% – 97%).
- Lot-to-Lot Consistency: Stringent QC testing performed on each lot to ensure consistent activity and purity.
- Bulk Quantities Available: Bulk up and save with large mass quantities to meet your research needs.
Supply agreements available, partner with us. Please contact us. - Our endeavor is to be the best and fastest recombinant proteins provider to the scientific community, with high quality, activity, and purity.
Product Datasheets
PRODUCT SPECIFICATIONS
| Applications |
|---|
|
Immunocytochemistry (ICC/IF)
|
|
Flow Cytometry (Flow)
|
|
ELISA (ELISA)
|
| Species Reactivity | |
|---|---|
|
Protein Construction
|
The DNA sequence encoding recombinant SARS-CoV-2 (2019-nCoV)
S1 (D614G) - Protein [His] (YP_009724390.1) (Val16-Arg685(D614G)) was expressed with
a poly-histidine tag at the C-terminus
|
|
Expressed Host
|
HEK293 Cells
|
|
Class
|
Protein/Antigen
|
|
Type
|
Recombinant
|
|
Clone
|
|
|
Immunogen
|
|
|
Conjugate
|
|
|
Form
|
Liquid or Solid
|
|
Concentration
|
|
|
Purification
|
|
|
Storage buffer
|
Contains
|
| More Details | |
|---|---|
|
Purity
|
> 98% based on SDS-PAGE determination
> 98% based on Rev-HPLC determination |
|
Endotoxin Level
|
< 1.0 EU/μg protein based on LAL method
|
|
Activity
|
Measured by its binding ability in a functional ELISA. Immobilized human
receptor protein ACE2 (Fc tag) at 2 μg/mL(100μL/well) can bind 2019-nCoV S1(D614G)-his
tag, the EC50 of 2019-nCoV S1(D614G) is 250-650 ng/mL.
|
|
Source
|
Novel coronavirus (2019-nCoV) or SARS CoV-2
|
|
N-terminal Sequence Analysis
|
Val16
|
|
Predicted Molecular Mass
|
76.41 kDa
|
|
SDS-PAGE
|
|
| Formulation Details | |
|---|---|
|
Formulation
|
Lyophilized from Sterile Phosphate buffer saline (pH 7.4)
*Prior to lyophilization, protectants such as mannitol, trehalose (at 5 % - 8 %), and Tween80 (at 0.01%) are usually added. The hardcopy of COA provides specific concentrations. For special requirements or any other concerns, please contact us on the given address or number. |
|
Reconstitution
|
Detailed instructions for reconstituting protein are included in the product
package. Please read the instructions carefully prior to starting the experiment.
|
|
Stability & Storage
|
Stable up to 12 months when stored at -20℃ to -80℃ under sterile
conditions
|
PROTEIN DESCRIPTION
The coronaviruses possess glycoprotein protrusions called spike (S) that interact with specific receptors present on the host cell. Some examples of these host receptors include include ACE2, (angiotensin-converting enzyme 2), APN (aminopeptidase N), CEACAM (carcinoembryonic antigen-related cell adhesion molecule 1), DPP4 (dipeptidyl peptidase-4), Sia (sialic acid), and O-ac Sia (O-acetylated sialic acid). The club-shaped spike protein contains several functional regions and two subunits S1 and S2. S1 (globular head region) contains the N-terminal receptor-binding domain (RBD) and the S2 stem region contains some basic elements (the C-terminal fusion domain, two heptad regions, a transmembrane domain, and a cytoplasmic tail) important for membrane fusion. The viral spike protein is critical for attachment of the virus with the host cell, resulting in fusion and virus entry into the cell. Aside from infection, spike proteins are also responsible for inducing neutralizing of antibodies, T-cell responses, and protective immunity. The spike proteins are the main target for vaccine design. They frequently mutate or undergo gene recombination of RBD allowing the virus to jump hosts, resulting in higher mortality rate.